- Allelica, a New York City-based genomics software company specializing in developing polygenic risk scores (PRSs) for common diseases, raised $1.75m in seed financing
- The round led by Valor Ventures, Sternberg Health, Pi Campus, as well as strategic business angels also participated in the round
- The proceeds of the financing will also used to advance clinical integration of the company’s PRS software into healthcare systems in the US
- A PRS is a measurement of a person’s risk of disease based on their genes and is based on combining the effects of a large number of genetic variants across the genome
- This information can used to stratify individuals based on their risk of disease
- By combining PRS with conventional risk factors, Allelica believes precision medicine at scale can achieved
